New asthma drug enters first human safety tests
NCT ID NCT06920901
Summary
This is an early-stage study to check the safety and side effects of a new drug called APG777 in adults with mild-to-moderate asthma. About 31 participants will be randomly assigned to receive either the drug or a placebo (inactive substance) for a year. The main goal is to see how well the drug is tolerated and how the body processes it, not to test how well it controls asthma symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site
La Jolla, California, 92037, United States
-
Investigational Site
Long Beach, California, 90808, United States
-
Investigational Site
San Jose, California, 95117, United States
-
Investigational Site
Torrance, California, 90505, United States
-
Investigational Site
Normal, Illinois, 61761, United States
-
Investigational Site
Kansas City, Missouri, 66160, United States
-
Investigational Site
Edmond, Oklahoma, 73034, United States
-
Investigational Site
Philadelphia, Pennsylvania, 19140, United States
-
Investigational Site
Pittsburgh, Pennsylvania, 15241, United States
-
Investigational Site
Bradford, West Yorkshire, BD9 6RJ, United Kingdom
-
Investigational Site
Manchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.